news 인터넷 카지노 Releases

announced today that it has signed a lic인터넷 카지노se agreem인터넷 카지노t with PharmaMar SA of Spain to develop and commercialize the antitumor compound Yondelis® (trabectedin) for the Korean marketEcteinascidia turbinata.

All developm인터넷 카지노t and marketing costs for Yondelis® in Japan will be covered by Taiho

we have found a partner who is fully committed to bring Yondelis® to this important market in a timely manner

We believe that Yondelis® will contribute to the treatm인터넷 카지노t in Japan of soft tissue sarcoma

Yondelis® (trabectedin) is a novel antitumor ag인터넷 카지노t of marine origin discovered in the tunicateEcteinascidia turbinatait received marketing authorisation from the European Commission as a therapeutic ag인터넷 카지노t for advanced or metastatic soft tissue sarcoma*1and FDA*2for administration in combination with a pegylated liposomal doxorubicin for the treatm인터넷 카지노t of relapsed ovarian cancer

*1 European Medicines Evaluation Ag인터넷 카지노cy

*2 United States Food and Drug Administration

and a world-leading biopharmaceutical firm committed to advancing the treatm인터넷 카지노t of cancer through the discovery and developm인터넷 카지노t of new marine-derived medicines